Smiley face
illustration of an eye
illustration to show how the eye is affected by fluid build up
illustration to show how the eye is affected by increased pressure
Illustration to show how the eye is damaged over time
1 2 3 Fluid builds up
inside your eye and
pressure increases As pressure increases,
it can damage your optic
nerve (which connects
your eye to your brain) Over time, this
damage to the optic nerve can
lead to vision loss
1 2 3
Fluid builds up inside your eye and pressure increases As pressure increases, it can damage your optic nerve (which connects your eye to your brain) Over time, this damage to the optic nerve can lead to vision loss
1 2 3
Fluid builds up inside your eye and pressure increases As pressure increases, it can damage your optic nerve (which connects your eye to your brain) Over time, this damage to the optic nerve can lead to vision loss
GLAUCOMA VISION
LOSS SIMULATOR

This simulator shows you how elevated eye
pressure may affect your vision over time

Just 1 DURYSTA® implant works for several months

DURYSTA® is a tiny, dissolvable implant your eye doctor places in your eye

  • The first and only FDA-approved dissolvable ocular implant to reduce eye pressure in people with open angle glaucoma or high eye pressure (ocular hypertension)
  • Just 1 DURYSTA® implant reduced eye pressure for 15 weeks in clinical studies
  • As DURYSTA® dissolves, it automatically releases medicine to help reduce high pressure inside your eye

DURYSTA® should not be given in the same eye more than once.

The most common side effect involving the eyes reported in patients using DURYSTA® was eye redness. Other common side effects reported were: feeling like something is in your eye, eye pain, being sensitive to light, a blood spot on the white of your eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

null null Not an actual DURYSTA® patient.

Meet Monica, a real glaucoma patient

Watch the video and learn about her
treatment journey with DURYSTA®

Monica started with eye drops to lower her eye pressure.
Later, her doctor recommended DURYSTA®
for several months of eye pressure control.

Learn why DURYSTA® has met her expectations.

Click to watch a video about Monica, a real DURYSTA® patient
null null

Monica is an actual DURYSTA® patient.

Resources to help on your own DURYSTA® journey

DURYSTA® Patient In-Office Screener

Find out if DURYSTA® is right for
you with this checklist.

Download it now and get
the conversation started.

: DURYSTA® Patient Savings Program Flashcard

Find out how the Savings
Program could benefit you.

Download the Savings Program
Flashcard to learn more.

Frequently Asked Questions About DURYSTA®

What is DURYSTA®?
How is the procedure done?
How does DURYSTA® work?
How might DURYSTA® help me?
Does DURYSTA® have any side effects?
How long will DURYSTA® work?
Is there a savings program?
Does DURYSTA® contain preservatives?
How small is the implant?

DURYSTA® may be right for you, too

Ask your eye doctor about DURYSTA®

Find out if DURYSTA® is right for you.

Here are some things to think about before speaking to your eye doctor:

Is elevated eye pressure an issue?

Do you understand elevated eye pressure and the risks associated with it?

Do you have difficulty applying your eye drops every day? (Hard time using them, or forgetting?)

: DURYSTA® Savings Program Card

Smiley face

Find an eye doctor near you who can prescribe DURYSTA®

null
: DURYSTA® Savings Program Card

Ask your doctor about the DURYSTA®
Savings Program—eligible commercially-insured patients pay $0* for up to one implant per eye

*Offer valid only for commercially-insured patients with plans covering DURYSTA; patient out-of-pocket expense may vary. Offer not valid for patients receiving reimbursement from Medicare, Medicaid, or any other federal, state, or government-funded healthcare program. See Program Terms, Conditions, and Eligibility Criteria here or visit www.durystasavingsprogram.com. Program Terms, Conditions, and Eligibility Criteria: 1. This offer is valid only for commercially-insured patients 18 years of age or older whose insurance plans cover DURYSTA® (bimatoprost intracameral implant) 10 mcg. 2. This offer is not valid for use by patients receiving reimbursement under any federal, state, or government-funded healthcare programs (e.g., Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs); private indemnity or HMO insurance plans that reimburse patients for the entire cost of their prescription drugs; or where prohibited by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any federal, state, or government-funded healthcare program, patient will no longer be eligible for this offer and must call IQVIA Inc. at 1-833-DURYSTA, option 2, to stop program participation. This offer is not valid for cash-paying patients. This offer is also not valid for commercially-insured patients whose insurance plans do not cover DURYSTA. 3. Depending on insurance coverage, eligible commercially-insured patients pay $0 for each of up to one (1) DURYSTA implant per eye. This offer applies to the implant only and does not apply to costs for any other medication, procedure, or diagnostic service. Check with healthcare provider and insurance plan for discount. Patient out-of-pocket expense may vary. 4. Primary payer benefits must be applied prior to submitting a savings request on behalf of a patient. Patients may not seek reimbursement for value received from the DURYSTA Savings Program from any third-party payers. 5. Offer applies to implants administered during the current program period of July 1, 2022 through June 30, 2023. Savings requests, including the DURYSTA Savings Program Physician Reimbursement Request Form, the CMS-1500 claim form, and the Explanation of Benefits (EOB) from the primary payer, must be submitted online at AllerganEyeCue.com or by fax to 1-866-676-4069 within 180 days after the product is administered to the patient. 6. Allergan, an AbbVie company, reserves the right to rescind, revoke, or amend this offer without notice. 7. Offer good only in the USA, including Puerto Rico. Patients residing in or receiving treatment in certain states may not be eligible to participate in this program. 8. Void if prohibited by law, taxed, or restricted. 9. This offer is not transferable. The selling, purchasing, trading, or counterfeiting of this offer is prohibited by law. 10. This offer has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified prescription. 11. This offer is not health insurance. 12. Program expires June 30, 2023. 13. By redeeming this offer, patient represents they meet the eligibility criteria above and patient understands and agrees to comply with the terms and conditions of this offer. For questions about the program, please call 1-833-DURYSTA, option 2, or email [email protected]. Program managed by IQVIA Inc. on behalf of Allergan, an AbbVie company.

INDICATIONS AND USAGE AND IMPORTANT SAFETY INFORMATION

USES

DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

IMPORTANT SAFETY INFORMATION

DURYSTA should not be used if:

  • You have any infection or suspected infection in your eye or surrounding eye area
  • You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems
  • You have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant)
  • The sack that surrounds the lens of your eye (posterior lens capsule) is missing or torn
  • You are allergic to any of its ingredients

DURYSTA may cause side effects involving the cornea, including increased risk of loss of cells from the inner layer of the cornea. You should not receive DURYSTA more than once in each eye. DURYSTA should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.

DURYSTA should be used with caution if you have narrow or obstructed iridocorneal angles (the space where the iris, the colored part of the eye, and cornea meet).

DURYSTA may cause swelling of the macula, the center spot of the retina (back of the eye). DURYSTA should be used with caution if your eye does not have a lens, if you have an artificial lens and a torn posterior lens capsule, or if you have any risk factors for swelling of the macula.

DURYSTA may cause inflammation inside the eye or make existing inflammation worse.

DURYSTA may cause increased brown coloring of the iris, which may be permanent.

Eye injections have been associated with infections in the eye. It is important that you contact your doctor right away if you think you might be experiencing any side effects after an injection, including eye redness, sensitivity to light, eye pain, or a change in vision. Your doctor should monitor you following DURYSTA administration.

The most common side effect involving the eyes reported in patients using DURYSTA was eye redness. Other common side effects reported were feeling like something is in the eye, eye pain, being sensitive to light, a blood spot on the white of the eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

Please see full Prescribing Information, or visit https://www.rxabbvie.com/pdf/durysta_pi.pdf.




IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE
COLLAPSE EXPAND

DURYSTA should not be used if:

  • You have any infection or suspected infection in your eye or surrounding eye area
  • You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems
  • You have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant)
  • The sack that surrounds the lens of your eye (posterior lens capsule) is missing or torn
  • You are allergic to any of its ingredients

DURYSTA may cause side effects involving the cornea, including increased risk of loss of cells from the inner layer of the cornea. You should not receive DURYSTA more than once in each eye. DURYSTA should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.

DURYSTA should be used with caution if you have narrow or obstructed iridocorneal angles (the space where the iris, the colored part of the eye, and cornea meet).

DURYSTA may cause swelling of the macula, the center spot of the retina (back of the eye). DURYSTA should be used with caution if your eye does not have a lens, if you have an artificial lens and a torn posterior lens capsule, or if you have any risk factors for swelling of the macula.

DURYSTA may cause inflammation inside the eye or make existing inflammation worse.

DURYSTA may cause increased brown coloring of the iris, which may be permanent.

Eye injections have been associated with infections in the eye. It is important that you contact your doctor right away if you think you might be experiencing any side effects after an injection, including eye redness, sensitivity to light, eye pain, or a change in vision. Your doctor should monitor you following DURYSTA administration.

The most common side effect involving the eyes reported in patients using DURYSTA was eye redness. Other common side effects reported were feeling like something is in the eye, eye pain, being sensitive to light, a blood spot on the white of the eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

Please see full Prescribing Information, or visit https://www.rxabbvie.com/pdf/durysta_pi.pdf.




© 2022 AbbVie. All rights reserved.

All trademarks are the property of their respective owners.

US-DUR-220188  12/22

Brought to you by